**Developmental drugs for idiopathic pulmonary fibrosis**

**Abstract**

***Introduction.*** Idiopathic pulmonary fibrosis (IPF) is an age-related lung disease of unknown cause characterized by relentless scarring of the parenchyma resulting in respiratory failure and death. The progressive and irreversible loss of lung function has a devastating impact on patients’ quality of life by causing debilitating dyspnea and cough. Two antifibrotic drugs (pirfenidone and nintedanib) are approved for the treatment of IPF worldwide, but they do not offer a cure and are associated with tolerability issues. Owing to its high unmet medical need, IPF is an area of dynamic research activity for the pharmaceutical industry.

***Areas covered.*** There is a growing portfolio of novel therapies that target different pathways involved in the complex pathogenesis of IPF. In this review, we discuss the mechanisms of action and available data for compounds in the most advanced stages of clinical trial development.

***Expert opinion.*** The approval of pirfenidone and nintedanib has fueled drug discovery and development in IPF, with new drugs likely to reach the clinic in the near future. However, a number of challenges remain, including combination therapy, evaluation of drug efficacy in clinical trials, route of administration (systemic vs. inhaled) and performance of early-phase proof of concept studies.

**Keywords:** idiopathic pulmonary fibrosis, novel drugs, therapy, clinical trials, treatment.

**Introduction**

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, age-related fibrotic interstitial lung disease (ILD) of unknown origin limited to the lung and associated with a pattern of fibrosis termed “usual interstitial pneumonia” (UIP) either radiologically on chest high resolution CT (HRCT) or histologically on lung biopsy (Raghu). As scar tissue replaces normal lung parenchyma, lung function is progressively and irreversibly lost leading to respiratory failure and eventually death. Median survival of IPF patients is 4 to 5 years, with older age and male sex being associated with a higher incidence of disease and shorter survival time after diagnosis (Raghu). Conservative estimates of disease incidence range from 3 to 9 cases per 100,000 per year in Europe and North America (Hutchinson), whereas the prevalence among individuals aged 65 years or older is as high as 494 cases per 100,000 (Raghu). Patients with IPF often carry multiple comorbid conditions (Raghu), which contribute to the substantial physical, psycho-social and economic burden of the disease. Accordingly, IPF represents an important public health problem (Diamantopoulos), and its burden is expected to steadily increase in the future with the population aging worldwide.

Following three decades of clinical research, two drugs (pirfenidone and nintedanib) have proven efficacious in slowing disease progression (as assessed by forced vital capacity (FVC), a measure of lung “size”) in patients with IPF (King; Richeldi); however, neither drug reverses lung fibrosis and up to one-quarter of patients may need to discontinue antifibrotic treatment due to tolerability issues (Galli). Lung transplant is available only to a highly selected minority of patients with IPF, and is associated with a 3-year and 5-year survival of only 66% and 53%, respectively (Valapour). Together, these limited treatment options illustrate the importance of developing and testing more efficacious and better tolerated therapies for IPF. In this review, we highlight promising novel agents for the treatment of IPF, with emphasis on those drugs in more advanced stages of development.

**Disease pathogenesis**

Our understanding of the mechanisms underlying IPF remains incomplete. This is due to both the lack of animal models of pulmonary fibrosis that translate perfectly to human disease and the multiplicity and complexity of co-activated fibrogenic pathways contributing to disease development. With these limitations, favored concepts of disease pathogenesis involve a complex interplay of genetic and environmental factors, ageing-associated processes and epigenetic reprogramming (Selman). In this scenario, persistent epithelial injury by various triggers activates several interrelated wound-healing pathways to restore homeostasis. Failure to contain or eliminate the inciting factors (i.e., smoking, microaspiration secondary to gastric reflux, occupational exposures, pollutants and occult viral infection, among others) results in continuous tissue damage and perpetuates the wound-healing response, leading to excessive deposition of extracellular matrix (ECM) component, and progressive scarring of the lung parenchyma and distal airways (Spagnolo). IPF is an age-related disease and is common in syndromes characterized by a cellular ageing phenotype (i.e., telomeropathies) (Armanios). In fact, senescent epithelial cells release a plethora of cytokines, chemokines and growth factors, thus promoting persistent activation and differentiation of fibroblasts to apoptosis-resistant myofibroblasts (Abbadie; Mora). Proliferating fibroblasts and myofibroblasts are organized in clusters termed *fibroblastic foci*, which represent microscopic areas of acute lung injury and are the histopathologic hallmark of UIP, the defining pattern of IPF (Katzenstein). The fibrotic remodeling of IPF lung makes it unlikely even for efficacious drugs to restore normal lung architecture and function. Therefore, the primary aim of developmental therapies for IPF is stabilization of lung function and prevention of further loss.

**Drugs in development**

***Drugs targeting fibroblasts***

*GLPG1690*. Lysophosphatidic acid (acyl-hydroxy-glycero-3-phosphates; LPA) is a bioactive phospholipid that mediates multiple cellular processes including survival, proliferation, differentiation and migration by signaling through cognate G protein-coupled receptors (Choi). Levels of LPA are increased in bronchoalveolar lavage (BAL) fluid from mice following intratracheal instillation of bleomycin, and genetic deletion of one of LPA receptors, LPA1, significantly protects animals from fibrosis and mortality in this model (Tager). In addition, pharmacological inhibition of LPA1 markedly reduces fibroblast migration following exposure to the BAL fluid of patients with IPF, suggesting that LPA-LPA1 signaling contributes to fibroblast recruitment and thus to fibrogenesis in IPF (Tager). Levels of autotaxin (ATX), the enzyme catalyzes lysophosphatidylcholine into LPA, *in vivo*, are also upregulated in IPF lungs, and inhibition of autotaxin attenuates experimental lung fibrosis (Oikonomou).

GLPG1690 is a potent and selective ATX inhibitor. In a phase I, first-in-human trial that evaluated safety, tolerability pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG1690 in eight male healthy subjects (including two who received placebo), the drug was generally safe and well tolerated (Van Der Aaar). In addition, GLPG1690 displayed good oral bioavailability with a PD response indicating target engagement. In a double-blind, placebo-controlled phase IIa study (FLORA), 23 patients with IPF were randomly assigned 1:3 to either oral GLPG1690 600 mg once daily (n=17) or placebo (n=6) for 12 weeks, with 20 patients completing the study (Maher). The drug was generally well tolerated with 11 patients (65%) experiencing mostly mild-to-moderate treatment-emergent adverse events (mainly infections and infestations). Notably, plasma levels of LPA C18:2, the most abundant LPA species in humans, were consistently reduced in the GLPG1690 group, indicating a biomarker effect. Moreover, as compared with placebo, the drug demonstrated favorable effects on mean change from baseline in FVC at week 12 (25 mL vs. -70 mL, respectively), although the study was not powered to detect between-group differences with regard to efficacy. Two identically designed, randomized, double-blind, placebo-controlled phase III studies (ISABELA 1 and 2) are currently being conducted in parallel to further evaluate the efficacy of GLPG1690 for the treatment of IPF (ClinicalTrial.gov Identifier: NCT03733444 and NCT03711162). In each study, 750 patients will be randomized in a 1:1:1 ratio to receive oral GLPG1690 600 mg, GLPG1690 200 mg or matching placebo once daily in addition to standard of care (i.e., pirfenidone, nintedanib, or neither). The primary endpoint is the rate of decline of FVC over 52 weeks, with all patients receiving randomized treatment until the last patient reaches 52 weeks of treatment. Key secondary endpoints include disease progression, defined as the composite endpoint of first occurrence of ≥10% absolute decline in per cent predicted FVC (%FVC) or all-cause mortality at week 52; time to first respiratory-related hospitalization over the entire treatment; or change from baseline in the St George’s Respiratory Questionnaire (SGRQ) total score (a measure of respiratory quality of life) at week 52 (Maher).

*FG3019/Pamrevlumab*. Connective tissue growth factor (CTGF) is a secreted glycoprotein produced by various cell types, including fibroblasts, myofibroblasts and endothelial cells. Despite its name, CTGF does not behave like a typical growth factor, as it does not bind to a unique receptor with high affinity to induce signal transduction. Instead, by interacting with various regulatory modulators, such as transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), and receptors such as integrins, it acts as a key regulator of several cellular responses such as cell adhesion and migration, angiogenesis and vascular permeability, myofibroblast activation, extracellular matrix deposition and tissue remodeling (Lipson). The biology of CTGF is complex and only partially understood; however, it is well established that CTGF plays a central role in the pathogenesis of diseases in which tissue remodeling and fibrosis occur. CTGF mRNA is overexpressed in the lung of patients with IPF and is localized predominantly to proliferating type II alveolar epithelial cells and activated fibroblasts in the interstitium (Pan). In addition, plasma levels of CTGF are significantly higher in patients with IPF than in patients with non-IPF ILD and healthy controls and correlate negatively with 6-month change in FVC (Kono). Pamrevlumab (FG-3019) is a fully human recombinant monoclonal antibody against CTGF. In a radiation-induced mouse model of pulmonary fibrosis, administration of FG-3019 reversed established lung remodeling and restored lung function (Bickelhaupt). In addition, CTGF blockade downregulated radiation-induced expression of genes associated with extracellular matrix remodeling and attenuated TGF-β induced epithelial-to-mesenchymal transition.

In an open-label, single-arm, phase II study, pamrevlumab administered at two doses (15 mg/kg and 30 mg/kg) by intravenous infusion every 3 weeks over a period of 48 weeks in patients with IPF (n=89) was safe and well tolerated (Raghu). In addition, the drug showed promising results in terms of change in lung function (2.7% decline in FVC from baseline to week 48 for the combined cohorts) and change in extent of pulmonary fibrosis by quantitative high-resolution CT (HRCT), with 16/46 (35%) of patients with a baseline FVC >55% predicted displaying stable or improved reticular fibrosis at week 48. The PRAISE study was a phase II, randomized, double-blind, placebo-controlled trial designed to assess the efficacy, safety and tolerability of pamrevlumab (30 mg/kg every three weeks for a total of 16 infusions over 48 weeks) in patients with IPF (n=103) (Richeldi). The primary efficacy outcome was the change from baseline in FVC % predicted at week 48. As compared with placebo, pamrevlumab significantly reduced both the decline of FVC (-2.9% vs. -7.2%, respectively; p=0.033) and the proportion of patients experiencing disease progression (defined as a decline in FVC % predicted ≥10% from baseline, or death; 10.0% vs. 31.4%, respectively; p=0.013) at week 48. Moreover, HRCT scores of quantitative lung fibrosis were significantly lower in the pamrevlumab than in the placebo arm at week 24 (24.8 mL vs. 86.4 mL; p=0.009) with a significant difference maintained through week 48 (75.4 mL vs. 151.5 mL; p=0.038). Pamrevlumab was well tolerated, with a safety profile similar to that of placebo. The efficacy and safety of pamrevlumab is being further evaluated in the phase III trial ZEPHYRUS (ClinicalTrial.gov Identifier: NCT03955146) that is currently recruiting.

*PBI-4050*. PBI-4050 (3-pentylbenzeneacetic acid sodium salt) is an orally active, low molecular weight compound with agonist activity towards the G-protein coupled receptors GPR40 and antagonist activity towards GPR84. By binding to GPR40 and GPR84, PBI-4050 inhibits the differentiation of fibroblasts to myofibroblasts and reduces the expression of pro-fibrotic markers such as CTGF and IL-6, resulting in reduced deposition of extracellular matrix proteins and fibrosis (Gagnon). PBI-4050 attenuates tissue fibrosis in multiple animal models, including the mouse model of bleomycin-induced pulmonary fibrosis wherein it significantly attenuates parenchymal disruption, alveolar wall thickness and fibrosis (Gagnon). A 12-week, phase 2, single-arm, open-label trial conducted at six sites across Canada evaluated the safety, tolerability and pharmacokinetics (PK) of oral PBI-4050 800 mg/daily alone or in combination with nintedanib/pirfenidone in patients with IPF (n=41) (Khalil). PBI-4050 was well tolerated both when given alone or in combination with nintedanib/pirfenidone. Indeed, while most patients experienced at least one adverse event (mainly diarrhea, nausea and headache), the majority of events were mild or moderate. Notably, the PK profile of the PBI-4050 + pirfenidone arm, which included 16 patients, showed shorter half-life, reduced absorption and lower maximum plasma concentration compared with the other treatment groups, consistent with a drug-drug interaction between PBI-4050 and pirfenidone (Khalil). The PBI-4050 + pirfenidone group displayed also a statistically significant mean decrease in FVC from baseline to week 12 (-102 ml; p=0.01).

*TD139*. Galectin-3 (Gal-3) is a β-galactoside-binding lectin expressed by a variety of cells, including alveolar macrophages, epithelial cells and lung fibroblasts, which plays a central role in inflammation and fibrosis (Henderson). In mice, genetic deletion of Gal-3 significantly attenuates bleomycin-induced pulmonary fibrosis by reducing TGF-β1-induced epithelial-to-mesenchymal transition, myofibroblast activation, and collagen production (Mackinnon). Increased levels of Gal-3 are found in the serum (Mackinnon) and BAL fluid (Nishi) from patients with IPF and are associated with interstitial lung abnormalities and impaired pulmonary function in undiagnosed research participants (Ho), suggesting a potential role for Gal-3 in early stages of pulmonary fibrosis. Accordingly, modulation of the Gal-3 pathway has been proposed as a potential therapeutic target in IPF. The safety, tolerability, PK and PD of TD139, an inhaled, dry powder, anti-Gal3 small molecule, has been evaluated in a randomized, double-blind, placebo-controlled, phase IIa trial in 24 IPF patients (ClinicalTrial.gov Identifier: NCT02257177) (Hirani). Three dose cohorts (0.3 mg, 3 mg and 10 mg) of 8 subjects each were evaluated in a 5:3 ratio (TD139:placebo) for 14 days. This study showed that TD139 is safe and well tolerated, and that TD139 administration led to target suppression as shown by Gal-3 expression on BAL macrophages. A phase IIb study of TD139 in IPF is currently recruiting participants (ClinicalTrial.gov Identifier: NCT03832946).

*αvβ6 inhibitors*. Integrins are transmembrane proteins that mediate cell attachment and migration by connecting the actin cytoskeleton to the extracellular matrix. Integrins also participate in more complex cellular events, including; survival, proliferation and regulation of gene expression (Werb). The integrin αvβ6, an epithelial restricted molecule, is a major activator of latent TGF-β, and mice lacking the β6 subunit are protected from bleomycin-induced and radiation-induced pulmonary fibrosis (Munger; Puthawala). In addition, αvβ6 is upregulated in the overlaying epithelial areas of fibrosis in patients with IPF (Xu). A phase IIb study evaluating the safety and tolerability of subcutaneously-administered, multiple escalating dose of STX-100/BG00011, a humanized monoclonal antibody directed against αvβ6, in patients with IPF has been terminated early due to safety concerns (NCT03573505; full results pending). Two studies are currently evaluating the safety and tolerability of the αvβ1, β3 and β6 selective inhibitor IDL-2965 in healthy subjects and individuals with IPF (ClinicalTrial.gov Identifier: NCT03949530), and the αvβ6 receptor occupancy (as assessed by PET) by the αvβ1 and β6 selective inhibitor PLN-74809 in patients with IPF (ClinicalTrial.gov Identifier: NCT04072315) (Table 1).

***Drugs targeting alveolar macrophages and their mediators***

*PRM151*. Pentraxin 2 (PTX-2), also known as serum amyloid P, is an endogenous plasma protein synthesized by the liver. PTX-2 is closely related to PTX-1 (C-reactive protein) and PTX-3, which is an acute-phase protein with an important modulatory role in tissue repair and remodeling (Doni). Thanks to its unique binding properties, PTX-2 localizes at sites of injury where it promotes resolution of inflammation and scarring by inhibiting the differentiation of monocytes into pro-inflammatory and pro-fibrotic macrophages and by promoting their differentiation into a regulatory phenotype (Pilling). PTX-2 accumulation and consumption at sites of fibrosis accounts for the low levels of circulating PTX-2 seen in several fibrotic diseases including IPF (Castaño).

PRM-151 is a fully recombinant form of the human PTX-2 protein, which ameliorates fibrosis in the bleomycin model of pulmonary fibrosis in mice (Murray). In an initial randomized, double-blind placebo-controlled, multiple ascending dose trial of 21 patients with IPF, PRM-151 was safe and well tolerated at all tested doses (1, 5, or 10 mg/kg), with no serious adverse reactions reported. In addition, PRM-151 increased PTX-2 levels by two- to eight-fold in a dose-dependent manner (van den Blink). Subsequently, in a phase II, double-blind trial, 117 patients with IPF were randomized to receive either recombinant human PTX-2 (rhPTX-2) 10 mg/kg i.v. (n=77) or placebo (n=39) every 4 weeks for 24 weeks (Raghu). Notably, 61 patients (79%) in the PTX-2 arm and 30 (77%) in the placebo arm were on concurrent IPF therapy (pirfenidone, n=39 (64%) and n=22 (73%), or nintedanib, n=22 (36%) and n=8 (27%), respectively). The study met its primary outcome of change from baseline to week 28 in mean FVC % predicted, which was -2.5 and -4.8 in the rhPTX-2 and placebo groups, respectively (p=0.001). Even more strikingly, the change in 6-minute walk distance (6MWD) was -0.5 m in the rhPTX-2 arm and -31.8 m in the placebo arm (difference, 31.3 m; p <0.001), although this effect was significant only in the subgroup without concurrent IPF therapy. Cough (18% vs. 5%), fatigue (17% vs. 10%), and nasopharyngitis (16% vs. 23%), the most common adverse events, were slightly more common in rhPTX-2-treated than placebo-treated patients (Raghu). In the open-label extension phase of the study, which was conducted to assess the safety and tolerability of PRM-151 up to 76 weeks, patients previously randomized to PRM-151 continued this treatment while those randomized to placebo crossed over to PRM-151 (Raghu). Long-term treatment with PRM-151 was well tolerated (compliance rate 99% and discontinuation rate 13.5%) with the reported adverse events being mostly symptoms or complications of IPF. In addition, as compared with the slopes for placebo, PRM-151 treatment was associated with favorable effects in terms of rate of decline in FVC % predicted and 6MWD both in patients on continued therapy and in those who crossed over from placebo. These data support further study of the efficacy of PRM-151 in slowing disease progression and improving functional status in larger populations of patients with IPF.

***Immunotherapies***

*IW001*. Type V collagen (Col V) is a regulatory fibril-forming collagen of the extracellular matrix that is found primarily within the fibrils of the major lung collagen type I. Col V interacts with matrix collagens and structural proteins to confer and preserve elasticity and structural integrity to the lung parenchyma (Mak). Despite being a native protein, Col V may act as a “foreign antigen” if exposed following lung injury, leading to an autoimmune response as shown in human and rodent studies of lung transplantation (Sumpter). Levels of Col V are increased in lung biopsies of patients with IPF (Parra), and Col V-induced tolerance abrogates fibrogenesis and down-regulates TGF-β-related signalling pathways in the bleomycin model of pulmonary fibrosis (Vittal). A phase 1, open-label study was designed to assess the safety, tolerability, and biological and clinical effects of three different doses (0.1, 0.5 and 1 mg/day) of IW001, a Col V oral immunotherapy, in anti-Col V Ab+ patients with IPF (n=30) (Wilkes). The drug was safe and well tolerated, with 100% of the patients completing the 24-week treatment period. In addition, while patients in the lowest-dose cohort experienced a decline in FVC comparable to that observed in placebo arms of previous IPF trials (Ley), the highest-dose cohort showed a trend toward stabilization of FVC and decreased binding of C1q (a collagen-like component of the complement system) to anti-Col V antibodies consistent with an IW001-induced effect on anti-Col V antibody binding and activity.

*VAY736/ianalumab*. Several lines of evidence suggest a potential role for humoral response in the development and progression of IPF. B cell-rich lymphocyte aggregates are a common finding in end-stage IPF lung tissue (Todd), and levels of anti-vimentin autoantibodies inversely correlate with lung function parameters (Li). In addition, detection of B-cell-activating factor (BAFF) is enriched in the lungs and blood of patients with IPF (Francois). Furthermore, rituximab, a B-lymphocyte depleting monoclonal antibody, has been used successfully as a rescue therapy in patients with severe ILD progressing despite conventional treatment, although this retrospective study did not include patients with IPF (Keir). VAY736/ianalumab is an IgG1 monoclonal antibody targeting BAFF-R that is being developed for the treatment of several immune-mediated conditions, including autoimmune hepatitis, rheumatoid arthritis, Sjögren’s syndrome and systemic lupus erythematosus. A currently ongoing phase II trial will evaluate the safety and efficacy of VAY736/ianalumab administered subcutaneously every 4 weeks for 48 weeks in patients with IPF (ClinicalTrial.gov Identifier: NCT03287414).

*GLPG1205*. GPR84 is a G-protein-coupled receptor expressed mainly in immune cells and upregulated under inflammatory conditions (Venkataraman). GPR84 has been associated with the induction of fibrosis in mice (Gagnon), and GPR84 mRNA is expressed IPF lung tissue, mainly in infiltrating immune cells and bronchial epithelial cells but absent in healthy human lung specimens (Saniere). GLPG1205 is a potent and highly selective GPR84 antagonist. In a bleomycin-model of pulmonary fibrosis in mice, GLPG1205 given orally for 14 days starting 7 days post-challenge significantly reduced the Ashcroft score and improved lung function compared to untreated diseased animals (Saniere). Similar results were observed in the irradiation model of pulmonary fibrosis. A phase II proof of concept study in patients with IPF is currently ongoing (ClinicalTrial.gov Identifier: NCT03725852).

***Drugs targeting broad pathways***

*KD025/SLx-2119*. The Rho-associated coiled-coil kinase (ROCK) isoforms 1 and 2 mediate a number of cellular functions, including adhesion, migration and phagocytosis, by regulating actin cytoskeleton dynamics (Olson). In lung fibrosis, ROCKs are activated by both biochemical (i.e., TGF-β, thrombin and LPA) and mechanical (i.e., increased matrix stiffness) stimuli (Knipe), and pharmacological inhibition of ROCK protects mice from experimentally induced lung fibrosis (Zhou). Both ROCK1 and ROCK2 contribute to the development of experimental pulmonary fibrosis by inducing exaggerated alveolar epithelial cell apoptosis, pulmonary vascular permeability, and fibroblast activation, suggesting that partial inhibition of either ROCK isoforms or both together has the potential to be an effective therapeutic strategy for pulmonary fibrosis (Knipe). An open-label phase II study assessed the safety, tolerability and efficacy of the ROCK2 selective inhibitor KD025/SLx-2119 400 mg once daily vs. standard of care (excluding nintedanib or pirfenidone) in 39 patients with IPF (Averill). The drug was safe and well tolerated and was associated with a numerically lower decline in FVC compared to standard of care without antifibrotic therapy.

*ND-L02-s0201/BMS-986263*. The 47-kDa heat shock protein (HSP47) is a collagen-specific molecular chaperone that plays a major role in the synthesis and assembly of various collagens (Masuda). HSP47 is strongly expressed in IPF lung tissue and is localized predominantly in α-smooth muscle actin-positive myofibroblasts and surfactant protein-positive type II pneumocytes (Iwashita). In addition, inhibition of HSP47 significantly improves bleomycin-induced pulmonary fibrosis in rats (Hagiwara). ND-L02-s0201/BMS-986263 is a lipid nanoparticle encapsulating a small interfering RNA (siRNA), which inhibits HSP47 expression. In the bleomycin model, ND-L02-s0201/BMS-986263 treatment significantly reduced lung weight, collagen deposition and histology and fibrosis scores (Zabludoff). A phase II, randomized, double-blind, placebo-controlled study is currently evaluating the safety, tolerability, biological activity, and PK of ND-L02-s0201 in patients with IPF (ClinicalTrial.gov Identifier: NCT03538301).

*CC-90001*. The stress-induced kinase c-Jun-N-terminal kinase (JNK) is an important modulator of cell death and, in some settings, a major driver of apoptosis (Dhanasekaran). JNK1 is a major regulator of TGF-β-induced epithelial-to-mesenchymal transition (Alcorn), and *JNK1*-/- mice are protected from TGF-β1- and bleomycin-induced profibrotic gene expression and pulmonary fibrosis (Alcorn). Using the mouse models of bleomycin- or adenovirus expressing active TGF-β1 (AdTGFβ1)-induced fibrosis, van der Velden and colleagues have recently demonstrated prominent activation of JNK in bronchial epithelia, whereas active JNK was observed in various regions of IPF lung tissue, including type I and type II pneumocytes and fibroblasts (van der Velden). In addition, ablation of *JNK1* from airway epithelia strongly protects from bleomycin- or AdTGFβ1-induced fibrosis and attenuates mesenchymal genes and proteins in lung tissue while preserving expression of epithelial genes (van der Velden). CC-90001 is a JNK1-biased inhibitor. In a phase Ib dose escalation safety study that included 100 healthy adults and 16 patients with pulmonary fibrosis, three dose of CC-90001 (100 mg, 200 mg and 400 mg, all once daily) were administered for 12 weeks (Bennett). The drug was safe and well tolerated, with nausea, the most common adverse event, being reported by 8-15% of subjects. The safety and efficacy of CC-90001 is currently being evaluated in phase II, 24-week, randomized, double-blind, placebo-controlled study

(ClinicalTrial.gov Identifier: NCT03142191).

**Conclusion**

Two drugs are approved worldwide for the treatment of IPF. However, the increasing incidence and poor prognosis of the disease make the search for more efficacious and better tolerated drugs an urgent need. Following promising early-phase data, several compounds targeting fibrogenic pathways potentially involved in disease pathogenesis are currently being developed. These will hopefully increase our portfolio of treatment options for this dreadful disease in the near future.

**Expert opinion**

The efficacy of pirfenidone and nintedanib in slowing functional deterioration and disease progression in patients with IPF demonstrates that the mechanisms driving progressive pulmonary fibrosis - at least some of them - are targetable and treatable. However, this is only *the end of the beginning* as a number of outstanding challenges in drug development in IPF remain, some of which are listed below.

*Identification of individuals at risk.* Owing to the relentlessly progressive nature of IPF, the identification of individuals at risk or with subclinical disease is of utmost importance. Intuitively, the earlier patients with IPF receive treatment, the more lung function remains to be preserved. Despite this rationale, IPF patients with less severe FVC impairment are less likely to receive antifibrotic treatment, potentially due to reimbursement restrictions (Moor). A subgroup analysis of pooled data from the INPULSIS trials has shown that patients with IPF and FVC >90% predicted experience the same rate of FVC decline and receive the same benefit from nintedanib as patients with more impaired lung function, which argues against the “watch and wait” approach in IPF patients with *mild* disease (Kolb).

*Route of administration.* Only a few clinical trials have investigated inhaled therapies in IPF. This is mainly due to concerns that fibrotic distortion of the airways may prevent drug deposition to the peripheral, subpleural regions of the lung - the optimal target of therapy in IPF. Maher and colleagues have recently demonstrated selective lung uptake of a target specific positron emission tomography (PET) ligand following a nebulized 1000 mcg dose of GSK3008348, a novel αvβ6 integrin inhibitor, in 8 patients with IPF (ClinicalTrial.gov Identifier: NCT03069989) (Maher). The galectin-3 inhibitor TD139 is another inhaled antifibrotic that is currently being investigated in a phase IIb trial (ClinicalTrial.gov Identifier: NCT03832946; Table 1). Another concern is that systemically administered drugs may not be suitable for inhaled delivery due to their physico-chemical properties or the necessary dose. A recent trial evaluated the PK and safety/tolerability profile of inhaled pirfenidone in healthy volunteers (n=30), healthy smokers (n=8) and patients with IPF (n=6) (Khoo). Inhaled pirfenidone was safe and well tolerated with mild, transient cough representing the most common drug-related adverse event. Moreover, PK data indicate that aerosolized pirfenidone 100 mg resulted in higher lung concentration and lower systemic exposure than those reported with oral pirfenidone at the dose approved in IPF (i.e., 2401 mg/daily). Inhaled drug delivery in IPF is feasible and deserves further investigation.

*How to judge efficacy*. With the approval worldwide of pirfenidone and nintedanib, future clinical trials in IPF will include patients on background antifibrotic treatment in their standard-of-care arms, rather than requiring patients to only be receiving a true placebo. This new standard-of-care will result in a slower rate of lung function decline in both the treatment and placebo arms, limiting the ability to detect a further benefit from a new potential therapy. While FVC remains the most practical to measure efficacy endpoint and a surrogate for mortality in trials testing antifibrotic compounds (Ley), composite endpoints for worsening disease and symptom burden (i.e., patient reported outcomes) should be further explored as clinically meaningful outcomes in IPF clinical trials, whether defined as “acute exacerbation” or “respiratory hospitalization.

*Combination therapy*. Due to the multitude of profibrotic pathways involved in disease pathogenesis (Wolters), IPF represents an ideal target for combination therapy. So far, three studies have explored the feasibility of combined treatment with nintedanib and pirfenidone in individuals with IPF (Ogura; Vancheri; Flaherty). These studies have shown that combination therapy (either nintedanib with add-on pirfenidone or vice versa) has a manageable safety profile in patients with IPF with no unanticipated adverse events. However, overall, about one-fourth of patients did not tolerate combination therapy, thus questioning its long-term tolerability. In addition, whether combination therapy adds benefit over single-agent therapy is unknown, as in these studies, the assessment of efficacy was only exploratory. There is a strong rationale for combination therapy in IPF, but this approach needs to be explored further.

*How to speed up drug development*. A multitude of compounds with promising preclinical profiles are currently being developed for IPF. However, positive effects in preclinical and early-phase studies translate poorly to efficacy in late stage clinical trials. In addition, early-phase studies in IPF have generally been too long, too large, and too dependent on clinical efficacy endpoints, which in this setting are only exploratory. Early-phase proof of concept studies should be faster, smaller, and with biological and mechanistic endpoints (Collard). This approach, which requires the use of human tissue-based investigations, has already proven successful in IPF (Maher) and has the potential to bridge the gap between early PK and PD data and the mechanism of action and biological activity of the compound under investigation.

**References**

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018;198:e44-e68

Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72

Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015;46:795-806

Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-30

Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. Pharmacoeconomics 2018;36:779-807

King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82

Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2016 annual data report: lung. Am J Transplant 2018;18:Suppl 1:363-433

Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and Nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology 2017; 22:1171-8

Spagnolo P, Cottin V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J Med Genet 2017;54:93-99

Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014;189:1161-72

Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012;13:693-704

Abbadie C, Pluquet O, Pourtier A. Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses? Cell Mol Life Sci 2017;74:4471-509

Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15

Mora AL, Rojas M, Pardo A, Selman M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov 2017;16:755-72

Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-86

Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54

Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2012;47:566-74

Van Der Aar EM, Fagard L, Desrivot J et al. Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690, a Potential New Treatment in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016;193:A2701

Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2A randomised placebo-controlled trial. Lancet Respir Med 2018;6:627-35

Maher TM, Kreuter M, Lederer DJ, et al. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) BMJ Open Respir Res 2019;6:e000422

Doni A, Musso T, Morone D, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med 2015;212:905-25

Pilling D, Roife D, Wang M, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007;179:4035-44

Castaño AP, Lin SL, Surowy T, et al. Serum amyloid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009;1:5ra13

Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010;5:e9683

van den Blink B, Dillingh MR, Ginns LC, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J 2016;47:889-97

Raghu G, van den Blink B, Hamblin MJ, et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA 2018;319:2299-307

Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med 2019;7:657-64

Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012;5(Suppl 1):S24

Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001;17:1220-7

Bickelhaupt S, Erbel C, Timke C, et al. Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst 2017;109(8)

Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 2011;412:2211-5

Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J 2016;47:1481-91

Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2020;8:25-33

Mak KM, Png CY, Lee DJ. Type V Collagen in Health, Disease, and Fibrosis. Anat Rec (Hoboken) 2016;299:613-29

Parra ER, Teodoro WR, Velosa AP, et al. Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia. J Histochem Cytochem 2006;54:1315-25

Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004;286:L1129-39

Vittal R, Mickler EA, Fisher AJ, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis. PLoS One 2013;8:e76451

Wilkes DS, Chew T, Flaherty KR, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1393-402

Ley B, Collard HR, King TE Jr. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2011;183:431-40

Gagnon L, Leduc M, Thibodeau JF, et al. A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84. Am J Pathol 2018;188:1132-48

Khalil N, Manganas H, Ryerson CJ, et al. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J 2019;53. pii:1800663

Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-71

Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-70

Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1–driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012;185:537-46

Nishi Y, Sano H, Kawashima T, et al. Role of Galectin-3 in Human Pulmonary Fibrosis. Allergol Int 2007;56:57-65

Ho JE, Gao W, Levy D, et al. Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. Am J Respir Crit Care Med 2016;194:77-83

Hirani N, Mackinnon A, Nicol L, et al. Td139, A Novel inhaled Galectin-3 inhibitor for the treatment if Idiopathic Pulmonary Fibrosis (IPF). Results from the first in (IPF) patients study. Am J Respir Crit Care Med 2017;195:A7560

Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008;20:242-8

Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev 2015;67:103-17

Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013;123:1096-108

Knipe RS, Probst CK, Lagares D, et al. The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. Am J Respir Cell Mol Biol 2018;58:471-81

Averill F, Albertson TE, Baratz DM,e t al. A Phase 2 Trial of KD025 to Assess Efficacy, Safety and Tolerability in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;195:A7560

Venkataraman C, Kuo F. The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. Immunol Lett 2005;101:144-53

Saniere L, Marsais F, Jagerschmidt C, et al. Characterization of GLPG1205 in mouse fibrosis models: a potent and selective antagonist of GPR84 for treatment of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019;199:A1046

Todd NW, Scheraga RG, Galvin JR, et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 2013;6:63-70

Li FJ, Surolia R, Li H, et al. Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J Immunol 2017;199:1596-605

Francois A, Gombault A, Villeret B, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun 2015;56:1-11

Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9

Masuda H, Fukumoto M, Hirayoshi K, Nagata K. Coexpression of the collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1994;94:2481-8

Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. Antisense oligonucleotide inhibition of Heat Shock Protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats. Respir Res 2007;8:37

Iwashita T, Kadota J, Naito S, et al. Involvement of collagen-binding heat shock protein 47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: contribution of type II pneumocytes to fibrosis. Hum Pathol 2000;31:1498-505

Zabludoff S, Liu Y, Liu J, et al. ND-L02-s0201 treatment leads to efficacy in preclinical IPF models. Eur Respir J 2017;50:PA881

Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008;27:6245-51

Alcorn JF, Guala AS, van der Velden J, et al. Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J Cell Sci 2008;121:1036-45

Alcorn JF, van der Velden J, Brown AL, McElhinney B, Irvin CG, Janssen-Heininger YM. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 2009;40:422-32

van der Velden JL, Alcorn JF, Chapman DG, et al. Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models PLoS One 2020;15:e0226904

Bennett B, Blease K, Ye Y, et al. CC-90001, a second generation Jun N-Terminal Kinase (JNK) inhibitor for the treatment of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;195:A5409

Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017;72:340-6

Moor CC, Wijsenbeek MS, Balestro E, et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res 2019;5(4). pii:00124-2019

Khoo JK, Montgomery AB, Otto KL, et al. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. J Aerosol Med Pulm Drug Deliv 2020;33:15-20

Maher TM, Simpson JK, Porter JC, et al. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respir Res 2020;21:75

Ley B. Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 2017;14:1383-4

Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J 2015;46:243-9

Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157-79

Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med 2018;197:356-63

Flaherty KR, et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J 2018;52(2). pii: 1800230 doi: 10.1183/13993003.00230-2018

Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1382-92

Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989;109:877-89

Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-28

Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008;177:82-90

Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol. 2009;174:1264-79